ArticleClinical and translational allergy2021
Patients with suspected allergic reactions to COVID-19 vaccines can be safely revaccinated after diagnostic work-up.
Article in Clinical and translational allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Pooled it
- Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis.JAMA internal medicine · 2022Pooled it
- Safety of COVID-19 revaccination in patients with prior hypersensitivity reactions: a retrospective study.Tropical diseases, travel medicine and vaccines · 2025Article
- Evaluating vaccination dosing strategies for SARS-CoV-2 in patients at high-risk for allergic reactions: Insights from vaccination campaign.The World Allergy Organization journal · 2025Article
- Incidence and Outcomes of COVID-19 Vaccine Hypersensitivity Reactions and Success of COVID-19 Vaccine Provocation Tests Post Previous COVID-19 Vaccine Hypersensitivity.Medicines (Basel, Switzerland) · 2024Article
- [Reasons for allergology consultations prior to COVID-19 vaccination and their outcomes : Two-year experience of an allergy center in North Rhine-Westphalia].Dermatologie (Heidelberg, Germany) · 2023Article
- Clinical Phenotypes of Immediate First-Dose Reactions to mRNA COVID-19: A Multicenter Latent Class Analysis.The journal of allergy and clinical immunology. In practice · 2023Article
- Polyethylene glycol/polysorbate skin testing can be useful in risk assessment and management of allergic/pseudoallergic reactions to nanolipid/adenoviral vaccines.The journal of allergy and clinical immunology. In practice · 2023Article
- From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Review
- Anaphylactic reactions after COVID-19 vaccination in Germany.Allergologie select · 2023Article
- SARS-CoV-2 and allergy - what have we learned after two and a half years?Allergologie select · 2023Review
- Fractionated vaccination with mRNA COVID-19 vaccine is safe for patients with polyethylene glycol allergy.Clinical and translational allergy · 2023Article
- PEG allergy - A COVID-19 pandemic-made problem? A German perspective.The World Allergy Organization journal · 2022Article
- Do basophil activation tests help elucidate allergic reactions to the ingredients in COVID-19 vaccines?Allergy · 2022Review
- Risk stratification through allergy history: single-centre experience of specialized COVID-19 vaccine clinic.Clinical and experimental immunology · 2022Article
- Experience with polyethylene glycol allergy-guided risk management for COVID-19 vaccine anaphylaxis.Allergy · 2022Article
- COVID-19 vaccines and anaphylaxis-evaluation with skin prick testing, basophil activation test and Immunoglobulin E.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2022Article
- Protocol of safe vaccination against COVID-19 in patients with high risk of allergic reactions.Clinical and translational allergy · 2022Article
- Why some people tolerate the second dose of a vaccine but not the first dose.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2022Article
- Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review.Microorganisms · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundWhen initiating the Danish vaccination program against COVID-19, the incidence of anaphylaxis was estimated to be 10 times higher compared to other virus-based vaccines. In this study, we present data on patients referred with suspected allergic reactions to COVID-19 vaccines. The main purpose of the study is to investigate the incidence and severity of the allergic reactions, and to evaluate the safety of revaccination.
methodsAll patients in the region of Southern Denmark with case histories of allergic reactions to COVID-19 vaccines in a defined period are included in this study. Diagnostic work up consisted of a detailed case history, evaluation of Brighton level of diagnostic certainty and World Allergy Organization grade of anaphylaxis and skin prick testing- and basophil histamine release testing with COVID-19 vaccines and relevant drug excipients. Patients were revaccinated at the Allergy Center when possible.
resultsSixty-one patients are included in this study. In 199,377 doses administered, nine patients fulfilled the criteria of anaphylaxis when using the Brighton Criteria (incidence being 45 per million). Of 55 patients with reactions to the first dose, 52 patients were revaccinated without adverse reactions. We found no proven cases of immediate anaphylaxis due to COVID-19 vaccines. By skin prick test, we diagnosed three patients with drug excipient allergy and further a patient with mastocytosis was found.
conclusionsAnaphylactic reactions to COVID-19 vaccines are rare and the incidence is similar to what is seen with other virus-based vaccines. Revaccination is safe in the majority of patients; however, allergological evaluation is important since some prove to have drug excipient allergy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.